CollPlant Biotechnologies (CLGN) and Stratasys Ltd. (SSYS) recently announced the initiation of a preclinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin 3D printer. The study is likely to focus on the ability of implants to grow natural breast tissue and completely degrade over time. As part of the study, 3D printed breast implants consisting of 200cc in the volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin printer are to be tested. The ...